

PRESS RELEASE

FOR IMMEDIATE RELEASE

Contact: Chris Lanham, RN

Phone: 248 288 2270

Americare announces new program to treat patients with MRSA, cost efficiently, in assisted care and institutional settings

Troy, MI, Americare Medical inc. has developed a proprietary program for treating Methicillin-resistant Staphylococcus aureus (MRSA) in the institutional setting including Assisted Care, Correctional Facilities and Group Homes.

MRSA occurs most frequently among patients who undergo invasive medical procedures or who have weakened immune systems and are being treated in hospitals and healthcare facilities such as nursing homes and dialysis centers. This type of bacteria causes “staph” infections that are resistant to treatment with usual antibiotics. Recently, Correctional facilities have observed an outbreak due to confined living quarters and close proximity of residents. MRSA in healthcare settings commonly causes serious and potentially life threatening infections, such as bloodstream infections, surgical site infections, or pneumonia states the Center for Disease Control and Prevention

The main mode of transmission to other patients is through human hands, especially healthcare workers' hands. Hands may become contaminated with MRSA bacteria by contact with infected or colonized patients. If appropriate hand hygiene such as washing with soap and water or using an alcohol-based hand sanitizer is not performed, the bacteria can be spread when the healthcare worker touches other patients, said Chris Lanham, R.N., Medical Director of AmeriStaff Nursing, a company subsidiary.

Company President Greg Jamian stated that people infected with antibiotic-resistant organisms like MRSA are more likely to have longer and more expensive hospital stays, and may be more likely to die as a result of the infection. When the drug of choice for treating their infection doesn't work, they require treatment with second- or third-choice medicines that may be less effective, more toxic and more expensive. We believe that we can save our customers 30-40% per episode with improved and proven clinical outcomes that patients tolerate better, said Jamian.